These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 28880414)

  • 1. Levodopa treatment and dendritic spine pathology.
    Nishijima H; Ueno T; Funamizu Y; Ueno S; Tomiyama M
    Mov Disord; 2018 Jul; 33(6):877-888. PubMed ID: 28880414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease.
    Nishijima H; Ueno T; Ueno S; Mori F; Miki Y; Tomiyama M
    Neurosci Res; 2017 Feb; 115():54-58. PubMed ID: 27773835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
    Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
    Nishijima H; Suzuki S; Kon T; Funamizu Y; Ueno T; Haga R; Suzuki C; Arai A; Kimura T; Suzuki C; Meguro R; Miki Y; Yamada J; Migita K; Ichinohe N; Ueno S; Baba M; Tomiyama M
    Mov Disord; 2014 Mar; 29(3):336-43. PubMed ID: 24573720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Nishijima H; Arai A; Kimura T; Mori F; Yamada J; Migita K; Wakabayashi K; Baba M; Ueno S; Tomiyama M
    Neuropathology; 2013 Aug; 33(4):391-6. PubMed ID: 23241013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.
    Fieblinger T; Cenci MA
    Mov Disord; 2015 Apr; 30(4):484-93. PubMed ID: 25759263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?
    Villalba RM; Smith Y
    Neuroscience; 2013 Oct; 251():2-20. PubMed ID: 23867772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
    Duty S
    CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Cerasa A; Pugliese P; Messina D; Morelli M; Gioia MC; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A
    Mov Disord; 2012 Mar; 27(3):364-71. PubMed ID: 22076870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glutamatergic synapses in Parkinson's disease.
    Gardoni F; Di Luca M
    Curr Opin Pharmacol; 2015 Feb; 20():24-8. PubMed ID: 25462288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
    Lago-Rodriguez A; Ponzo V; Jenkinson N; Benitez-Rivero S; Del-Olmo MF; Hu M; Koch G; Cheeran B
    Exp Brain Res; 2016 Dec; 234(12):3659-3667. PubMed ID: 27566172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
    Suarez LM; Solis O; Aguado C; Lujan R; Moratalla R
    Cereb Cortex; 2016 Oct; 26(11):4253-4264. PubMed ID: 27613437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spine Enlargement of Pyramidal Tract-Type Neurons in the Motor Cortex of a Rat Model of Levodopa-Induced Dyskinesia.
    Ueno T; Nishijima H; Ueno S; Tomiyama M
    Front Neurosci; 2017; 11():206. PubMed ID: 28450828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.